Aberrant WNT signaling underlies cancerous transformation and growth in many tissues,
such as the colon, breast, liver, and others. Downregulation of the WNT pathway is a desired …

A promising novel target for anti-cancer therapy is the tumour vasculature. Both primary
tumour growth and the formation of metastasis depend on the establishment of new blood …

The infection of human colonic epithelial cells HT-29 by human immunodeficiency virus type
1 (HIV-1) occurs independently of CD4, the main HIV-1 receptor expressed on lymphocytes …

OBJECTIVE No satisfactory treatment for adrenocortical carcinoma (ACC) is available. We
investigated the efficacy and toxicity of suramin In the treatment of metastatic ACC since …

Suramin is a novel anticancer agent that blocks the binding of growth factors, including basic
fibroblast growth factor (bFGF), to their receptors. Prior studies showed human and …

A high-performance liquid chromatography (HPLC) method for the determination of suramin,
its precursors and analogues in a aqueous solutions and in plasma samples with …

✓ Suramin, a polyanionic compound, has been shown to inhibit the binding of various
growth factors to cell surface receptors. The effects of suramin on 125 I-insulin-like growth …

The conformational requirements of suramin for its binding to basic fibroblast growth factor
(bFGF) and platelet-derived growth factor (PDGF) were examined by molecular modeling …

Suramin and suramin analogues strongly inhibit both nucleotide interaction with the
nucleotide-binding site of granulocyte-macrophage colony-stimulating factor (GM-CSF) and …

Suramin is a polysulfonated compound currently under investigation for the treatment of
various types of cancer. Pharmacokinetic studies from clinical trials in humans have shown …